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Abstract
Background Little is known regarding variations in pre-
operative treatment and practice for rectal cancer (RC) on
an international level, yet practice variation may result in
differences in recurrence and survival rates.
Methods One hundred seventy-three international colo-
rectal centers were invited to participate in a survey of
preoperative management of rectal cancer.
Results One hundred twenty-three (71%) responded, with
a majority of respondents from North America, Europe,
and Asia. Ninety-three percent have more than 5 years’
experience with rectal cancer surgery. Fifty-ﬁve percent
use CT scan, 35% MRI, 29% ERUS, 12% digital rectal
examination and 1% PET scan in all RC cases. Seventy-
four percent consider threatened circumferential margin
(CRM) an indication for neoadjuvant treatment. Ninety-two
percent prefer 5-FU-based long-course neoadjuvant che-
moradiation therapy (CRT). A signiﬁcant difference in
practice exists between the US and non-US surgeons: poor
histological differentiation as an indication for CRT (25%
vs. 7.0%, p = 0.008), CRT for stage II and III rectal cancer
(92% vs. 43%, p = 0.0001), MRI for all RC patients (20%
vs. 42%, p = 0.03), and ERUS for all RC patients (43% vs.
21%, p = 0.01). Multidisciplinary team meetings signiﬁ-
cantly inﬂuence decisions for MRI (RR = 3.62), neoadju-
vant treatment (threatened CRM, RR = 5.67, stage II ? III
RR = 2.98), quality of pathology report (RR = 4.85), and
sphincter-saving surgery (RR = 3.81).
Conclusions There was little consensus on staging, neo-
adjuvant treatment, and preoperative management of rectal
cancer. Regular multidisciplinary team meetings inﬂuence
decisions about neoadjuvant treatment and staging methods.
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A uniform international consensus regarding the optimal
management of rectal cancer patients has yet to be devel-
oped. Recommendations and guidelines have been pub-
lished [1–11], but guidelines may lag behind current
standards in therapy and it is not known if they are used
consistently or universally, even within their respective
countries. Differences in practice may inﬂuence rectal
cancer survival and morbidity. Furthermore, adherence to
evidence-based clinical practice in colorectal surgery has
been shown to be inconsistent in several reports [12, 13].
Scientiﬁc comparison of staging and preoperative
treatment of rectal cancer may be hindered by the variety
of practice patterns within countries and across interna-
tional borders. In this context, it is important to evaluate
inherent international trends and differences in the man-
agement and treatment of rectal cancer. We have con-
ducted a survey regarding current practices of preoperative
staging and treatment of rectal cancer among an interna-
tional panel of colorectal surgeons. The aim of the study
was to identify regional differences among international
experts that may inﬂuence our interpretation of current and
future studies regarding the preoperative management of
rectal cancer. Furthermore, we wanted to detect the impact
of multidisciplinary team meetings and department case-
load upon the preoperative decision-making.
Materials and methods
The study group
A group of six surgeons from the US, Australia, and
Europe constituted the working members of an Interna-
tional Rectal Cancer Study Group (IRCSG). All surgeons
had more than 10 years of experience with rectal cancer.
IRCSG is an independent group without ﬁnancial support
from any companies or organizations and has representa-
tives from Asia, Europe, and North America. The aim of
the study group was to evaluate current international
treatment practices of rectal cancer.
Invited colorectal surgeons to IRCSG
Centers and representative surgeons were selected based on
prior publications, presentations, or participation at
national or international meetings and via a PubMed search
for scientiﬁc reports on rectal cancer. All respondents were
invited to become members of IRCSG. To ensure an
experienced international panel, we used two strategies:
1. PubMed search We performed an unsystematic search
using the search term rectal cancer combined with
staging, treatment, chemotherapy, radiation, surgery.
Based upon this search, corresponding authors were
identiﬁed and included in the survey sample.
2. Oral presentation at an international scientiﬁc meeting
The working committee of IRCSG participated in
several international rectal cancer conferences from
2006 to 2008. Oral presenters in these conferences
were identiﬁed and included in the survey sample.
The questionnaire
The questionnaire was developed and validated during
several meetings of IRCSG. The aim was to cover all
aspects of preoperative rectal cancer treatment. Modiﬁca-
tions to the survey items were made by literature review
and e-mail discussions. The questionnaire consisted of 59
questions. An average of 20 min was needed to complete
the questionnaire.
Study logistics
The survey was sent to the identiﬁed colorectal surgeons
both as a document attached to an e-mail and as a
Web-based survey link forwarded to each participant. The
Web-based option was offered through SurveyMonkey.
com. Two follow-up e-mails were sent to nonresponders,
and the survey was open for a total of 16 weeks.
Review of national guidelines
Six central rectal cancer treatment guidelines were
reviewed (Table 1) to compare national recommendations
for radiological T staging and neoadjuvant treatment. The
aim was to gain insight in similarities and differences of
guideline recommendations.
Statistics
Descriptive statistics were performed by percentages,
2 9 2 contingency tables, and Fisher’s exact test. For
comparison purposes, respondents were divided into three
groups: US-based surgeons, non-US surgeons, and total.
Bivariate logistic regression analyses were performed to
detect the impact (measured by relative risk [RR]) of
department caseload and team meetings upon preoperative
decision-making. All tests were two-sided and p\0.05
was considered statistically signiﬁcant. All data were
analyzed using SPSS v.16.1 (SPSS, Inc., Chicago, IL).
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123Results
One hundred seventy-three colorectal surgeons were
identiﬁed and contacted via e-mail. After one initial e-mail
and two follow-up e-mails, 123 (71%) surgeons responded.
One hundred one responded via the Web-based question-
naire, 20 by returning the questionnaire as an e-mail
attachment, and 2 by fax. Of those that returned the survey,
110 (89%) fully completed all parts of the questionnaire.
Demographics (Table 2)
The colorectal centers were located in 28 countries repre-
senting ﬁve continents: 53 in North America, 43 in Europe,
18 in Asia, 8 in South America, and 1 in Africa. Seventy-
eight percent were university hospitals.
Rectal surgery experience (Table 2)
Ninety-three percent of responding surgeons have more
than 5 years’ experience with rectal cancer surgery, and
70% work in departments that manage more than 50 rectal
cancers per year. Twenty percent of the surgeons perform
more than 50 rectal cancer operations annually.
Preoperative staging (Table 3)
Fifty-ﬁve percent of surgeons prefer CT scan, 35% MRI,
29% rectal ultrasound, 12% digital rectal examination, and
1% PET scan in all rectal cancer patients for preoperative
staging. All use more than one imaging modality in all
rectal cancer patients for preoperative staging. Signiﬁcantly
more non-US surgeons use MRI on all rectal cancer
Table 1 Guideline recommendations for radiologic T staging and neoadjuvant treatment of rectal cancer [2, 6–8, 10, 11]
NCCN USA
2009
World Congress
2007
French
Guidelines
2007
Norwegian
Guidelines 2008
ESMO 2008 Danish
Guidelines 2009
Radiological
T staging
MRI Either MRI
or ERUS all
patients
All patients (best to
assess CRM, but
ERUS ? CT can
also be used)
All T3–T4
or N? after
ERUS
All patients MRI on all T3–T4 All patients
ERUS Either MRI
or ERUS all
patients
ERUS ? MRI
or ERUS ? CT
All patients ERUS on all early
tumors (T1–T2)
ERUS on all early
tumors (cT1–T2)
ERUS on all
early tumors
CT CT abdomen/
thorax all
patients not
recommended
for T staging
CT abdomen/thorax
all patients
CT thorax/
abdomen all
patients
CT pelvis is an
alternative to
MRI when no
access to MRI
CT abdomen/thorax all
patients (alternatively
chest X-ray and
ultrasound of liver)
CT thorax/
abdomen all
patients
PET scan Not routinely
indicated
Indicated only when
lesions in liver
Not routinely
indicated
NA NA Only indicated
when suspicion
of extrahepatic
metastasis
Neoadjuvant
treatment
T1–2, N0 No neoadjuvant
treatment
RCT T2 No neoadjuvant
treatment
No neoadjuvant
treatment
No neoadjuvant
treatment
No neoadjuvant
treatment
T3, N0 or T
any, N1–2
(stage II or
III)
RCT Radiation alone
or RCT
Radiation alone
or RCT (no
treatment to
T3N0 with
CRM[1 mm)
See CRM No RCT early T3.
Radiation alone
or RCT
RCT midrectal
T3 with CRM
\5 mm. All
low rectal T3
T4 RCT RCT Radiation alone
or RCT
RCT RCT RCT to mid and
low T4
CRM NA NA Radiation or
RCT when
CRM\1m m
CRM\3m m
RCT
NA See T3
NCCN National Comprehensive Cancer Network, ERUS endoscopic rectal ultrasound, CRM circumferential margin, NA no information,
RCT chemoradiotherapy
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123patients compared to US surgeons (42% vs. 20%,
p = 0.03). US surgeons prefer ERUS signiﬁcantly more
than non-US surgeons do (43% vs. 21%, p = 0.01). Sim-
ilarly, we detected a difference in PET scan use: 53% of
non-US surgeons and 25% of US surgeons never use PET
scan (p = 0.005).
Indications for preoperative chemoradiotherapy (CRT)
(Table 4)
Eighty-one surgeons (73%) consider threatened circumfer-
ential margin (CRM) an indication for neoadjuvant treat-
ment. Of those, 40% consider 1 mm or less, 39% consider
2 mm or less, and 21% consider 3 mm or less as threatened
CRM. Sixty-seven (61%) always give neoadjuvant treat-
ment to both stage II and stage III rectal cancer patients.
However, two US surgeons and two non-US surgeons
answered ‘‘others’’ for ‘‘give preoperative CRT treatment to
all T3 cancers and greater,’’ which means stage II or higher.
Ninety-two percent of US surgeons compared to 43%
non-US surgeons give CRT for stage II and stage III rectal
cancers (p = 0.0001). A signiﬁcantly higher proportion of
US surgeons consider rectal cancer with poor histological
differentiation an indication for CRT (10/39 vs. 5/71,
p = 0.008). Cancer in the distal third of the rectum is an
indication for preoperative CRT for 15 (14%) surgeons,
while cancer in the distal two-thirds is used by ﬁve (5%)
surgeons, and one (1%) gives neoadjuvant treatment to all
rectal cancer patients.
Neoadjuvant treatment and other preoperative
considerations (Table 5)
Ninety-two percent prefer 5-ﬂuorouracil (5-FU)-based
long-course neoadjuvant CRT. Ten percent (4) of the US
surgeons and 16% (12) of non-US surgeons prefer
short-course radiation therapy. A signiﬁcantly higher pro-
portion of the US surgeons have radiation therapy available
at their hospital (89% vs. 74%, p = 0.04), and signiﬁcantly
more of non-US surgeons have regular rectal cancer audits
(74% vs. 51%, p = 0.01).
Institutional radiation rate (Fig. 1)
Twenty-nine of 39 US surgeons have an institutional irra-
diation rate (IRR)[50% and 31/71 non-US surgeons have
an IRR[50% (p = 0.001). However, nine (8%) surgeons
answered that their institution offers radiation to more than
90% of all rectal cancer patients, and a similar proportion
(8%) have an IRR of 10–29%.
Impact of multidisciplinary teams and caseload
(Table 6)
Departments with regular multidisciplinary team meetings
are morelikely topreferMRIforlocal staging (RR = 3.62),
and there is a trend toward signiﬁcance (p = 0.06). Simi-
larly, patients with threatened circumferential margin are
more likely to receive neoadjuvant treatment in departments
with team meetings (RR = 5.67, p = 0.03). Other signiﬁ-
cant impacts of team meetings were found upon pathology
report quality (RR = 4.85, p = 0.01), new chemotherapy
regimeniftherearelivermetastases(RR = 6.41,p = 0.02),
and one-stage surgery when there are liver metastases
(RR = 0.25,p = 0.02).Similar inﬂuences ofcaseloadupon
preoperative decision-making were not observed.
Discussion
This is the ﬁrst survey of current practice among interna-
tionalcolorectalcentersregardingpreoperativemanagement
of rectal cancer. The results demonstrate a wide variation
Table 2 Hospital afﬁliation, department caseload, and rectal cancer
surgical experience (n = 123)
US [n (%)] Non-US [n (%)] Total [n (%)]
Hospital location
City 1 (2.3) 11 (13.9) 12 (9.8)
Rural 1 (2.3) 0 1 (0.8)
Private 7 (15.9) 7 (8.8) 14 (11.4)
University 35 (79.5) 61 (77.2) 96 (78.0)
Experience
\5 years 4 (9.1) 4 (5.0) 8 (6.5)
5–10 years 12 (27.3) 17 (21.5) 29 (23.6)
11–20 years 16 (36.4) 27 (34.1) 43 (35.0)
[20 years 12 (27.3) 31 (39.2) 43 (35.0)
RC surgeries/year
\10 2 (4.5) 3 (3.7) 5 (4.1)
10–20 10 (22.7) 18 (22.7) 28 (22.8)
21–30 10 (22.7) 24 (30.3) 34 (27.6)
31–50 14 (31.8) 18 (22.7) 32 (26.0)
[50 8 (18.2) 16 (20.2) 24 (19.5)
Hospital caseload
\10 0 2 (2.5) 2 (1.6)
11–30 4 (9.1) 4 (5.0) 8 (6.5)
31–50 11 (25.0) 16 (20.2) 27 (22.0)
51–70 7 (15.9) 13 (16.4) 20 (16.3)
71–90 11 (25.0) 21 (26.5) 32 (26.0)
[90 11 (25.0) 23 (29.1) 34 (27.6)
Experience Respondents experience with rectal cancer surgery,
RC surgeries/year Respondents caseload of rectal cancer surgery,
Hospital caseload Number of rectal cancer surgeries performed at the
department each year
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123in preoperative staging procedures, inconsistencies in indi-
cations for preoperative CRT, and differences in treatment
procedures for identical rectal cancers. These variations
highlight the need for more and better scientiﬁc evidence to
help guide rectal cancer treatment as well as the need for
international focus upon development of guidelines.
There exist several guidelines for rectal cancer treat-
ment, at both national and international levels. New
guidelines have recently been published [9]. However,
these guidelines vary in their recommendations (Table 1).
Similarly, practice may vary between countries and conti-
nents because surgeons prefer treatment according to their
own guidelines. Implementation of national guidelines of
clinical practice seems slow, as pointed out in other sur-
veys [12, 13] and has been demonstrated among colorectal
surgeons [14–18]. The differences in preoperative staging
and treatment options cannot be explained by the hetero-
geneity of the institutional afﬁliations of the participants.
As the vast majority of the responding colorectal surgeons
work in academic medical centers, the differences in cur-
rent practices reﬂect the lack of clinical evidence or the
slow implementation of such evidence. Evidence from the
US about adherence to preoperative staging and treatment
options suggests marked variation. For the eight centers
that participate in the National Comprehensive Cancer
Network (NCCN), adherence to guidelines and quality
measures is variable [18]. Concordance with guidelines is
recently discussed in an editorial by Browman [19].
Certainly, it is important to indicate how well a recom-
mendation is aligned with the evidence from which it is
derived, but it is uncertain how practitioners interpret,
respond to, or act upon a recommendation. We think our
study reﬂects this argument, showing inconsistent practice
also within continents and national borders.
Variations in preoperative staging imaging will select
identical rectal cancer patients to undergo different treat-
ment regimens depending on the sensitivity and speciﬁcity
of the selected imaging modality. MRI and rectal ultra-
sound have better diagnostic properties than CT for rectal
cancer [20, 21], but still CT is used for local staging by
54.5% of the surgeons compared to 34.5% that prefer MRI
for all rectal cancer patients. The distance to the CRM has
been increasingly recognized as an important factor and a
surrogate marker for local recurrence. In this context, MRI
has increased in popularity because of its ability to help
decide the distance to the CRM and it should be used
widely for preoperative treatment planning. CT has little or
no place in describing the distance to the CRM because of
its low spatial resolution. A recently published review
recommends the use of MRI for all rectal cancer patients
[22]. In our study, 11% of respondents never use MRI and
approximately 50% use it in selected cases. In our opinion
these numbers are surprisingly low and might reﬂect the
slow implementation of evidence-based medicine among
colorectal surgeons. All centers in this study use more than
one staging procedure. CT has a role in evaluating the
Table 3 Preference of image
modality for staging of rectal
cancer
Question: Which of the
following procedures for rectal
cancer staging do you use in
your daily practice? (Please
choose an answer for each
method)
All of the responding surgeons
use more than one imaging
modality in all rectal cancer
patients
MRI magnetic resonance
imaging, ERUS endoscopic
rectal ultrasound,
CT computerized tomography,
PET scan positron emission
tomography, DRE under GA
digital rectal examination under
general anesthesia, NS not
signiﬁcant
US [n (%)] Non-US [n (%)] Total [n (%)] p value
MRI
Never 7 (17.9) 5 (5.0) 13 (11.8) NS
Selected 24 (61.5) 35 (49.2) 59 (53.6) NS
All 8 (20.5) 30 (42.2) 38 (34.5) 0.03
ERUS
Never 2 (5.1) 10 (14.0) 12 (10.9) NS
Selected 20 (51.3) 46 (64.7) 66 (60.0) NS
All 17 (43.6) 15 (21.1) 32 (29.1) 0.01
CT
Never 6 (15,4) 13 (18.3) 19 (17.3) NS
Selected 11 (28,2) 20 (28.1) 31 (28.2) NS
All 22 (56,4) 38 (53.5) 60 (54.5) NS
PET scan
Never 10 (25.6) 38 (53.5) 48 (43.6) 0.005
Selected 28 (71,8) 33 (46.4) 61 (55.5) 0.01
All 1 (2.6) 0 (0.0) 1 (0.9) NS
DRE under GA
Never 20 (51.3) 43 (60.5) 63 (57.3) NS
Selected 16 (41.0) 18 (25.3) 34 (30.9) NS
All 3 (7.7) 10 (14.0) 13 (11.8) NS
Total (missing) 39 (5) 71 (8) 110 (13)
World J Surg (2010) 34:2689–2700 2693
123inﬁltration of other organs, usually for large T4 tumors.
In addition, CT is used to determine metastatic disease in
the liver and/or lungs (M stage in the TNM classiﬁcation).
Endoscopic rectal ultrasound (ERUS) has a role in evalu-
ating small tumors for which local excision might be fea-
sible. Retrospectively, it might be argued that some
surgeons participating in the survey answered the question
with respect to M staging and that this might bias the
results regarding CT use (54% use it on all patients).
However, the questionnaire speciﬁcally says ‘‘CT scan of
the pelvis,’’ i.e., local staging, which reﬂects the actual use
of CT for local staging (either alone or in combination with
other modalities). In contrast, we do believe that CT is the
most common modality for M staging.
Generalization of the results from this study must be
made with care. The invited surgeons were selected based
upon publications listed in PubMed and presentation or
participation at national or international meetings, thus
respondents could be prone to selection bias. However, the
respondents were from large university hospitals through-
out the world (78%) as well as from other large hospitals
with a relatively high volume of rectal cancer patients, and
the participants are all published authors and teachers at
national meetings. Similarly, the surgical experience
among the respondents is high: 93% of the responding
surgeons have experience with rectal cancer treatment for
more than 5 years, and 35% have experience for more than
20 years (Table 2). Thus, in our opinion the respondents
are thoroughly experienced and good representatives for
their national rectal cancer practice.
This survey has revealed prominent variations in
practice standards in the preoperative staging and treat-
ment of rectal cancer. The survey emphasizes the need for
establishing an international consensus for the manage-
ment of patients with rectal cancer and for identifying
areas for future research. An international consensus is
needed in order to develop staging and preoperative
treatment standards if outcomes are to be compared
Table 4 Indications for preoperative chemoradiotherapy
US [n (%)] Non-US [n (%)] Total [n (%)] p value
All RC 0 1 1 (0.9) NS
Stage II and III RC 36 (92.3) 31 (43.6) 67 (60.9) 0.001
CRM B1m m
a 13 (33.3) 27 (38.0) 40 (36.4) NS
CRM B2m m
a 10 (25.6) 28 (39.4) 38 (34.5) NS
CRM B3m m
a 4 (10.3) 17 (23.9) 21 (19.1) NS
Mesorectal growth C5m m
a 5 (12.8) 16 (22.5) 21 (19.1) NS
Mesorectal growth C5m mB15 mm
a 2 (5.1) 5 (7.0) 7 (6.4) NS
Any RC in distal third of rectum 4 (10.3) 11 (15.4) 15 (13.6) NS
Any RC in distal two-thirds of rectum 3 (7.7) 2 (2.8) 5 (4.5) NS
Any RC with poor differentiation 10 (25.6) 5 (7.0) 15 (13.6) 0.008
Total (missing) 39 (5) 71 (8) 110 (13)
CRM circumferential margin, CRT chemoradiotherapy, RC rectal cancer
a Assessed by MRI, ERUS (endoscopic rectal ultrasound), or CT
Question: Which indications do you follow as indications for neoadjuvant treatment? (Please choose all that apply to you)
Indications for neoadjuvant treatment other than those listed: 1. Age of patient. 2. Nodal status, vascular invasion status. 3. Local ﬁxity/invasion
of adjacent organ on CT. 4. Any margins at risk, multiple nodes, and/or deep extension into mesorectum. 5. No CRT for proximal stage II rectal
cancers. 6. N2 on MRI. 7. Selected stage I disease before local excision—part of a national trial. 8. Stage II or III in the lower 1/3 rectal cancer. 9.
Anterior tumor, distal 1/3 rectum in a male patient. 10. Stage III in the lower third and inﬁltration of the sphincter. 11. Stage II or III low rectal
cancers and T4 cancer any level.12. MRI threatened margin, long-course CRT. For those with clear margin, short-course CRT. Any nodal
disease, long-course CRT. 13. Preoperative staged higher than T3N1. 14. Distal third, not cT1 (all cT3 or cN? or cT2 in lower third). 15.
Presumed positive lymph node on MRI. 16. Bulky tumor. 17. More than four suspected LN (N2). 18. T3–T4, any suggestions of LN involvement.
19. Fixed rectal cancers or rectal cancers with large lymph nodes only. 20. T3 cancers, T2 cancers with enlarged nodes, tumors below the
peritoneal reﬂection. 21. T3 male mid, lower rectal cancer, T4 female mid, lower rectal cancer. 22. Proportionally big tumors for the pelvis. 25.
Histology: lymphovascular invasion. 26. Any cT3- or cN? rectal cancer of the distal third; any ultralow T1/T2 cancer when sphincter
preservation is a goal; bulky tumors of distal and middle third in male patients. 27. Lower threshold for CRT in lower third. 28. Fixed rectal
cancers or rectal cancers with large lymph nodes only. 29. Sphincter involvement. 30. Anterior locations in males. 31. All N?. 32. Nodal
involvement on preoperative imaging. 33. Large T3 and all T4 tumors (long course) and some borderline T2/T3 tumors (short course)
independent of preop nodal status. 34. T4 cancers, multiple large lymph nodes, iv growth. 35. Candidates for APR and severe tumor ﬁxation by
digital rectal examination. 36. Anterior tumor. 37. Stage III rectal cancer, before Miles operation. 38. Locally advanced and stage III rectal
cancers. 39. T4 cancer below the peritoneal reﬂection. 40. Enlarged nodes on imaging; T3 or greater; close enough to anorectal ring that
shrinkage with neoadjuvant therapy may improve chance of sphincter-sparing surgery in patient with good performance status. 41. uT3, uT4,
uN?. 42. Big tumors at the lower third of the rectum, especially in males. 43. But not all small posterior T3N0. 44. Positive mesorectal nodes on
imaging
2694 World J Surg (2010) 34:2689–2700
123between institutions and countries. Focusing on stan-
dardization and documentation as a process may also
improve results [23]. The survey also points out the need
for agreement on the staging and neoadjuvant treatment
modalities used if we are to compare outcomes in rectal
cancer treatment.
The different indications for neoadjuvant treatment will
select noncomparable groups of patients in outcome
studies. Different staging procedures and treatment algo-
rithms could certainly reﬂect the published differences in
local recurrence rates and 5-year cancer-speciﬁc survival
rates [24, 25]. Heald [26] standardized the surgical tech-
nique for rectal cancer surgery with a signiﬁcant impact on
the risk of local recurrence. Probably an evidence-based
standardization of preoperative practices will also beneﬁt
rectal cancer patients [27].
Table 5 Neoadjuvant treatment and preoperative considerations
US
[n (%)]
Non-US
[n (%)]
Total
[n (%)]
p value
Threatened CRM as an indication for neoadjuvant therapy 26 (66.7) 55 (77.4) 81 (73.6) NS
Short-course radiation therapy (5 Gy 9 5)
a 4 (10.3) 12 (16.9) 16 (14.5) NS
Long-term chemoradiation regimen (1.8–2 Gy 9 25)
a 37 (94.9) 64 (90.1) 101 (91.87) NS
Other neoadjuvant therapy 2 (5.1) 11 (15.4) 13 (11.8) NS
Radiation therapy available 35 (89.7) 53 (74.6) 88 (80.0) 0.04
Intraoperative radiation therapy available 11 (28.2) 14 (19.7) 25 (22.7) NS
Internal sphincter-saving surgery in case of complete tumor response after neoadjuvant
therapy
22 (56.4) 34 (47.8) 56 (50.9) NS
External sphincter-saving surgery in case of complete tumor response after neoadjuvant
treatment
5 (12.8) 11 (15.4) 16 (14,5) NS
Alternation of neoadjuvant treatment if synchronous liver metastasis 20 (51.3) 28 (39.4) 48 (43.6) NS
Treatment plans within an interdisciplinary team 37 (94.9) 60 (84.5) 97 (86,6) NS
Only specialized centers 33 (84.6) 60 (84.5) 93 (83) NS
Abdominoperineal resection is a surrogate marker for the quality of RC surgery 15 (38.5) 39 (54.9) 54 (48.2) NS
Weekly/monthly RC audits 20 (51.3) 53 (74.6) 73 (65.2) 0.01
Total (missing) 39 (5) 71 (8) 110 (13)
CRM circumferential margin
a Thirteen (11.8%) surgeons report different practice than short- or long-course CRT, i.e., 8 oxaliplatin-based CRT, 1 long-term chemoradiation
but wait 8–10 weeks, 1 short-term radiation with delayed surgery (5–7 weeks), 1 both regimens depending on MRI ﬁndings, 1 no radiation
Fig. 1 Institutional irradiation
rate (IRR) for rectal cancer
at 123 international centers.
Signiﬁcantly more US centers
(29/39) have IRR[50%
compared to non-US centers
(31/71) (p = 0.001)
World J Surg (2010) 34:2689–2700 2695
123Table 6 Impact of caseload and multidisciplinary teams upon preoperative descision-making
Relative risk p 95% conﬁdence interval
Lower bound Higher bound
Staging method
MRI Cload 1.33 0.21 0.82 2.15
Team 3.62 0.06 0.93 14.03
ERUS Cload 0.89 0.80 0.54 1.47
Team 3.12 0.23 0.65 15.03
PET Cload 1.24 0.11 0.93 1.66
Team 2.27 0.16 0.73 7.07
CT Pelvis Cload 1.30 0.14 0.96 2.06
Team 0.67 0.62 0.27 6.78
DRE Cload 1.15 0.27 0.86 1.52
Team 1.17 0.79 0.38 3.61
Indication for neoadjuvant treatment
Stg II ? III Cload 1.24 0.07 0.91 1.68
Team 2.98 0.08 0.91 9.74
CRM Cload 1.06 0.69 0.73 1.33
Team 5.67 0.003 1.80 17.89
Mesorectal\5 mm Cload 1.09 0.60 0.77 1.55
Team 1.60 0.55 0.33 7.73
Mesorectal 5–15 mm Cload 0.99 0.99 0.55 1.78
Team \0.01 0.99 \0.01 \0.01
Distal 1/3 Cload 0.97 0.91 0.64 1.48
Team \0.01 0.91 \0.01 \0.01
Distal 2/3 Cload 1.84 0.09 0.90 3.76
Team \0.01 0.99 \0.01 \0.01
Poor differentiation Cload 0.74 0.14 0.50 1.10
Team 1.71 0.45 0.41 7.14
Other preoperative preferences
Pathology report Cload 1.17 0.45 0.77 1.76
Team 4.85 0.01 1.34 17.46
IORT Cload 1.36 0.11 0.94 1.97
Team \0.01 0.99 \0.01 \0.01
SSS initial imaging Cload 1.00 0.88 0.76 1.34
Team 3.81 0.09 0.98 14.72
New regimen liver met Cload 1.38 0.03 0.52 0.97
Team 6.41 0.02 1.34 30.64
One-stage surgery Cload 1.23 0.17 0.91 1.64
Team 0.25 0.02 0.08 0.80
APR rate\10% Cload 1.00 0.91 0.72 1.39
Team 1.05 0.87 0.31 3.90
IRR[50% Cload 0.91 0.59 0.66 1.26
Team 0.22 0.01 0.62 0.78
Cload caseload, divided into 6 groups, see Table 1, Team = regular multidisciplinary team meetings to plan rectal cancer treatment, MRI magnetic
resonance imaging, ERUS = endoscopic rectal ultrasound, PET PET scan, DRE digital rectal exam under anesthesia, Stg II ? III stage II and III rectal
cancer, CRM use of the preoperatively assessed circumferential margin (by CT, MRI, or ERUS) as an indication of neoadjuvant treatment, Mesorectal
\5m mtumor mesorectal growth less than 5 mm, Mesorectal 5–15 mm tumor mesorectal growth 5–15 mm, Distal 1/3 any cancer located in distal 1/3 of
the rectum, Distal 2/3 any cancer located in the distal 2/3 of rectum, Poor differentiation any cancer with histological description of poor differentiation,
Pathology report pathology report always describes the circumferential resection margin measured in mm, IORT intraoperative radiation therapy
available, SSS initial imaging sphincter-saving surgery decided upon initial imaging, New regimen liver met new regime of neoadjuvant treatment if
synchronous rectal cancer and liver metastases, One-stage surgery one-stage surgery if resectable rectal cancer and liver metastasis, APR rate \10%
institutional abdominoperineal resection rate less than 10%; IRR[50% institutional irradiation rate greater than 50%
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123The wide variation in indications for neoadjuvant
treatment and radiation rates should alert both national and
international rectal cancer expert organizations as well as
health-care administrators. The individualized treatment
plans for rectal cancer patients should reﬂect the com-
plexity of the disease and not geography or the surgeons’ or
institutions’ preferences and traditions. Establishment of
multidisciplinary teams (MDTs) comprising surgeons,
oncologists, radiologists, and pathologists can hopefully
elevate the decisions regarding the individual rectal cancer
patient to a level where documentation and up-to-date
knowledge are focused. In our study we have shown that
MDTs signiﬁcantly inﬂuence preoperative decision-
making (Table 6). Interestingly, regular MDT meetings
signiﬁcantly inﬂuence decisions on choice of staging
modality, neoadjuvant treatment, and several other critical
factors in the preoperative planning of rectal cancer treat-
ment. We believe that regular MDT meetings will improve
guideline adherence and quality of rectal cancer care, as
recently addressed by Taﬂampas [22]. According to our
analysis, department caseload does not have as much
inﬂuence on preoperative decision-making.
Over-andunderstagingaswellasover-orundertreatment
will have an impact on health-care costs, frequency of side
effects of CRT, and surgery, including a patient’s quality of
life and local recurrence and cancer-speciﬁc survival. Con-
tinuous education of rectal cancer surgeons seems necessary
to increase implementation of evidence-based clinical
practice. Heath-care authorities should develop quality
control systems in order to ensure adherence to national and
international recommendations and guidelines. The national
and international societies associated with rectal cancer
treatment have the challenge of developing such updated
evidence-based recommendations.
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Appendix
The following surgeons participated in the International
Rectal Cancer Study Group (IRCSG) (listed alphabetically
by last name): Ambrosetti, Patrick MD (University Hos-
pital of Geneva, Geneva, Switzerland). Andujar, Jose MD
(West Penn Allegheny Health System, Pittsburgh, PA,
USA). Baixuli, Jorge MD, PhD (Division of Colorectal
Surgery, Department of General Surgery, Clı ´nica
Universidad de Navarra, Navarra, Spain). Balen, Enrique
MD, PhD (Department of Colorectal Surgery, Hospital de
Navarra, Pamplona, Spain). Baxter, Nancy MD, PhD
(Li Ka Shing Knowledge Institute of St. Michael’s Hos-
pital, University of Toronto, Toronto, ON, Canada). Beck,
David MD (Ochsner Clinic Foundation, New Orleans, LA,
USA). Bemelman, Willem MD (Academic Medical Centre,
Amsterdam, Netherlands). Bergamaschi, Robert MD, PhD,
FRCS, FASCRS, FACS (Division of Colon & Rectal
Surgery, State University of New York, NY, USA), Bill-
ingham, Rick MD (Department of Surgery, University of
Washington, Seattle, WA, USA). Birch, Daniel MSc MD,
FCRCS, FACS (Royal Alexandra Hospital, University of
Alberta, Edmonton, AL, Canada). Bonardi, Renato MD
(Universidade Federal Do Parana, Curitiba, Brazil).
Bonardi, Marcos MD (University of Sa ˜o Paulo Medical
School, Sa ˜o Paulo, Brazil). Bonjer, Jaap MD (Queen
Elizabeth II Health Sciences Centre, Dalhousie University,
Halifax, NS, Canada). Braga, Marco MD (San Raffaele
University, Italy). Buch, Harikesh MS, FRCS, FRCS (T.N.
Medical College & B.Y.L. Nair Hospital, Mumbai, India).
Buechler, Markus MD (Department of Surgery, University
of Heidelberg, Heidelberg, Germany). Burnstein, Marcus
MD (St Michael’s Hospital, University of Toronto,
Toronto, ON, Canada). Campbell, Kenneth MB ChB,
MD(hons) FRCS(Ed) (Ninewells Hospital & Medical
School, Dundee, UK). Caushaj, Philip MD (Temple
University Clinical Campus at The Western Pennsylvania
Hospital, Pittsburgh, PA, USA). Celebrezze, James MD
(Allegheny General Hospital, Pittsburgh, PA, USA).
Chang, George MD (The University of Texas, M. D.
Anderson Cancer Center, Houston, TX, USA). Cheong,
Denis MD (Tan Tock Seng Hospital, Singapore). Cohen,
Jeffery MD, FACS, FASCRS (Department of Surgery,
University of Connecticut, Storrs, CT, USA). Colak,
Tahsin MD (Medical Faculty of Mersin University, Mersin,
Turkey). Delaney, Conor MD, PhD (University Hospitals
Case Medical Center, Cleveland, OH, USA). Dhoore,
Andre MD, PhD (University Hospitals Gasthuisberg,
Leuven, Belgium), Douglas, Philip MD (St. George and
Prince of Wales Hospitals, Sydney, Australia). Dozois, Eric
MD, PhD (Mayo Clinic, Rochester, MN, USA). Efron,
John MD (Mayo Clinic, Scottsdale, AZ, USA), Ellis, Neal
MD (Surgery, University of South Alabama, Mobile, AL,
USA). Enker, Warren MD (Memorial Sloan-Kettering
Cancer Center, New York, NY, USA). Fanelli, Robert D
MD, FACS, FASGE (Department of Surgery, University of
Massachusetts Medical School, Worchester, MA, USA).
Fazio,Victor MB, BS, FRACS, MS (Department of Sur-
gery, Lerner College of Medicine, Case Western Reserve
University and Cleveland Clinic Foundation, Cleveland,
OH, USA). Fleshman, James MD (Washington University,
St Louis, MO, USA), Franklin, Morris MD (Texas
Endosurgery Institute and Baylor College of Medicine,
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123University of Texas Health Science Center, San Antonio,
TX, USA). Fry, Robert MD (Department of Surgery, The
University of Pennsylvania School of Medicine, Philadel-
phia, PA, USA). Garcia-Aguilar, Julio MD, PhD (Univer-
sity of California, San Francisco, CA, USA). Garcia-
Granero, Eduardo MD, PhD, EBSQ-C (Department of
Surgery, Hospital Clinico Universitario, University of
Valencia, Valencia, Spain). Habr-Gama, Angelita MD
(University of Sa ˜o Paulo School of Medicine, Sa ˜o Paulo,
Brazil). Hahnloser, Dieter MD ESBQ Coloproctology
(University Hospital, Zurich, Switzerland). Harris, Guy
MD (St. Richards Hospital, Chichester, UK). Hasegawa,
Hirotoshi MD, FRCS (Keio University School of Medi-
cine, Tokyo, Japan). Holm, Torbjorn MD, PhD (Depart-
ment of Surgery, Karolinska University Hospital,
Stockholm, Sweden). Horgan, Paul PhD, FRCS (Academic
Surgery, University of Glasgow, Glasgow, Scotland).
Hyman, Neil MD, FACS (College of Medicine, University
of Vermont, Burlington, VT, USA). Irwin, Terry MD
(Royal Victoria Hospital, Belfast, Northern Ireland). Joh,
Yong-Geul (Hansol Hospital, Seoul, South Korea). Jongen,
Johannes MD (Park-Klinik, Kiel, Germany). Kaiser,
Andreas MD (Keck School of Medicine, University of
Southern California, Los Angeles, CA, USA). Kang, Sun-
Bum MD (Department of Surgery, Seoul National Uni-
versity Bundang Hospital, Seoul, South Korea). Kariv,
Yehuda MD (Tel Aviv Sourasky Medical Center, Tel Aviv,
Israel). Kennedy, Robin MB ChB, MS, FRCS (St. Mark’s
Hospital, London, UK). Kessler, Hermann MD (University
of Erlangen-Nurnberg, Nurnberg, Germany). Khan,
Mohammad MD (L & D Hospital, Luton, UK). Kim, Seon-
Hahn, MD (Korea University Anam Hospital, Seoul, South
Korea). Krokowicz, Piotr MD, PhD (Department of Gen-
eral and Colorectal Surgery, Poznan University of Medical
Sciences, Poznan, Poland). Kwok, Samuel MD (Hong
Kong Sanatorium & Hospital, Hong Kong). Lacy, Antonio
MD (Hospital Clinic, University of Barcelona, Barcelona,
Spain). Larson, David MD (Mayo Clinic, Rochester, MN,
USA), Law, Wai Lun MS, FRCS (Ed.), FACS (Department
of Surgery, University of Hong Kong Medical Center,
Queen Mary Hospital, Hong Kong). Lee, Ed MD (Albany
Medical Center, Albany, NY, USA). Lindsetmo, Rolv-Ole
MD, PhD (Department of Surgery, University Hospital
North Norway, Tromsø, Norway). Lippert, Hans MD
(University Hospital of Magdeburg, Magdeburg, Ger-
many), Ludwig, Kirk MD (Duke University Medical
Center, Durham, NC, USA), Lynch, Andrew Craig MD
(Peter MacCallum Cancer Center, Melbourne, Australia).
MacRae, Helen MA, MD, FRCSC (University of Toronto
and Mt. Sinai Hospital, Toronto, ON, Canada). Madbouly,
Khaled MD, MS, PhD (Department of Surgery, University
of Alexandria, Alexandria, Egypt). Maeda, K. MD (Fujita
Health University, Toyoake, Japan). Marderstein, Eric MD,
MPH (Department of Surgery, University Hospitals Case
Medical Center, Cleveland, OH, USA). Marino, Mario MD
(Department of Surgery, University of Torino, Torino,
Italy). Marks, John MD (Lankenau Hospital and Institute of
Medical Research, Wynnewood, PA, USA). Maurer, Chr-
istoph MD FACS FRCS (Department of Surgery, Hospital
of Liestal, University of Basel, Liestal, Switzerland).
McLeod, Robin MD (University of Toronto, Toronto, ON,
Canada). Monson, John MD PhD (University of Hull,
Castle Hill Hospital, Hull, UK). Mortensen, Neil MD (The
John Radcliffe Hospital, Oxford, UK), Neary, Paul MD
(Adelaide and Meath Hospital incorporating the National
Children’s Hospital, Dublin, Ireland). Newstead, Graham
MB BS, FRACS, FRCS(Eng), FACS, FASCRS, Hon
FRSM, Hon FACP (Department of Surgery, University of
New South Wales, Sydney, Australia). O’Brien, David MD
(Legacy Portland Hospitals, Oregon Health & Science
University, Portland, OR, USA). Orangio, Guy MD
(Georgia Colon and Rectal Associates, Atlanta, GA, USA).
Orkin, Bruce MD (The George Washington University,
Washington, DC, USA). Page, Michael MD, FACS,
FASCRS (Iowa Clinic, Des Moines, IA, USA). Pa ˚hlman,
Lars MD, PhD (Department of Surgery, Uppsala Univer-
sity Hospital, Uppsala, Sweden). Panis, Yves MD
(Department of Surgery, Assistance Publique des Hopitaux
de Paris, Paris, France). Panton, Neely MB, BS, FRCSC,
FACS (Division of General Surgery, University of British
Columbia, Vancouver, BC, Canada). Pennickx, Freddy
MD, PhD (University Hospital, University of Leuven,
Leuven, Belgium). Phang, Terry MD, MSc, FRCSC,
FACS, FASCRS (Department of Surgery, University of
British Columbia,Vancouver, BC, Canada). Pinedo Man-
cilla, George MD (Catholic University School of Medicine,
Santiago, Chile). Post, Stefan MD (University Hospital
Mannheim, University of Heidelberg, Heidelberg, Ger-
many). Rafferty, Janice MD (University of Cincinnati,
Cincinnati, OH, USA). Rajput, Ashwani MD (University of
New Mexico, Albuquerque, NM, USA). Reis Neto, Jose
Alfredo dos MD, PhD (Department of Surgery, Catholic
University of Campinas, Campinas, Brazil). Reynolds,
Harry MD (University Hopsitals Case Medical Center,
Cleveland, OH, USA). Rivadeneira, David MD (Stony
Brook University Hospital Medical Center, Stony Brook,
NY, USA). Roselli, Jorge MD (University Hospital,
Bogota, Colombia). Rosen, Harald MD, EBSQ Coloproc-
tology (Department of Surgery, St. Vincent Hospital,
Department of Surgery, Vienna, Austria). Rossi, Gustavo
MD (Division of Colon and Rectal Sugery, Hospital Itali-
ano de Buenos Aires University of Buenos Aires, Buenos
Aires, Argentina). Rouanet, Philippe MD, PhD (Chirurgie
Oncologique CRLC Val d’Aurelle, Montpellier, France).
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123Rullier, Eric MD (Department of Surgery, University Hos-
pital of Bordeaux, Bordeaux, France). Schiedeck, Thomas
MD (Department in Surgery, Klinik fu ¨r Allgemein- und
Viszeralchirurgie, Klinikum Ludwigsburg, Ludwigsburg,
Germany). Schiessel, Rudolf MD (Danube Hospital/SMZ-
Ost,Vienna,Austria).Schlachta,ChristopherBSc,MDCM,
FRCSC, FACS (Departments of Surgery and Oncology,
Schulich School of Medicine and Dentistry, London Health
Sciences CentreUniveristyHospital,London,ON,Canada).
Schwenk,WolfgangMD,PhD(Charite ´ UniversityMedicine
BerlinCampusMitte,Berlin,Germany).Senagore,Anthony
MD, MS, MBA, FACS, FASCRS (Department of Surgery,
Michigan State University, Spectrum Health Care, Grand
Rapids, MI, USA). Seow-Choen, Francis MD (Seow-Choen
Colorectal Centre, Mount Elizabeth Medical Centre,
Singapore). Sim, Richard MD (Tan Tock Seng Hospital,
Singapore). Sing, Wong Kutt MD (Yong Loo Lin School of
Medicine,Singapore).Stamos, MichaelMD (Departmentof
Surgery, University of California Irvine Medical Center,
Orange, CA, USA). Sternberg, Jeffrey MD (San Francisco
Surgical Associates, San Francisco, CA, USA). Tuckson,
WayneMD(UniversityofKentucky,Lexington,KY,USA).
Ugolini, Giampaolo MD, PhD (Universita ` di Bologna,
Bologna, Italy). Vaccaro, Carlos MD (Hospital Italiano de
BuenosAires,BuenosAires,Argentina).Vargas,DavidMD
(University of Kentucky, Lexington, KY, USA). Vignali,
Andrea MD (Department of Surgery, IRCCS San Raffaele-
UniversityVitaesalute,Milan,Italy).Vonen,BartholdMD,
PhD (Department of Surgery, University Hospital North
Norway, Tromsø, Norway). Weiss, Eric MD, FACS, FAS-
CRS, FACG (Colorectal Surgery, Cleveland Clinic Florida,
Fort Lauderdale, FL, USA). Wexner, Steven MD, FACS,
FRCS,FRCS(Department ofColorectalSurgery,Cleveland
Clinic Florida, Weston, FL, USA). Whiteford, Mark MD,
FASCRS (Providence Cancer Center, Oregon Health and
Science University, Portland, OR, USA). Wibe, Arne MD,
PhD (Department of Surgery, St. Olavs Hospital, University
ofTrondheim,Trondheim,Norway). Williams,NormanMS
FRCSFMedSci(DepartmentofSurgery, TheRoyal London
Hospital, Whitechapel, London, UK). Woods, Ron MD
(St Vincent’s Hospital, Melbourne, Australia), Yamamoto,
Takayuki MD, PhD, FACG (Yokkaichi Social Insurance
Hospital, Yokkaichi, Japan), Young-Fadok, Tonia MD
(Mayo Clinic Arizona, Scottsdale, AZ, USA).
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